Slide 1: Ipca Laboratories Ltd. Corporate Presentation
Ipca Laboratories Ltd. Corporate Presentation Dec 2022 1
Slide 2: Company Overview
Company Overview Incorporation : 1949 Present Management : Since 1975 Total income F. Y. 2021-22 : Rs. 5455.49 Crs / US$ 733 Mn (Standalone) Rs. 5896.36 Crs / US$ 792 Mn (Consolidated) Exports F. Y. 2021-22 : Rs. 2502.69 Crs / US$ 336 Mn Business Model : Integrated pharmaceutical company producing B
Slide 3: Five Years' Highlights Standalone
Five Years’ Highlights Standalone 2017-18 2018-19 2019-20 2020-21 2021-22 Domestic Income ( Rs. Crs ) 1,694.54 1,956.90 2,288.37 2,484.21 2,952.80 Domestic Income (US $ Mn) 239.21 276.24 323.03 333.94 396.56 Export Income ( Rs. Crs ) 1,564.21 1,730.84 2,143.75 2,717.19 2,502.69 Export Income (US $ M
Slide 4: Five Years' Highlights Consolidated
Five Years’ Highlights Consolidated 2017-18 2018-19 2019-20 2020-21 2021-22 Domestic Income ( Rs. Crs ) 1,694.68 1,956.90 2,327.88 2,519.77 3,077.75 Domestic Income (US $ Mn) 239.23 276.24 328.61 338.72 413.34 Export Income ( Rs. Crs ) 1,630.69 1,873.96 2,387.83 2,963.06 2,818.61 Export Income (US $
Slide 5: Manufacturing Facilities: Formulations
Manufacturing Facilities Formulations 5
Slide 6: Manufacturing Facilities: Formulations
Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections UK-MHRA, TGA-Australia, WHO-Geneva, EU Certification by German Authority, Health Canada, GCC, MOH- Athal Columbia, FDA Ghana, MOH Oman, NDA - Uganda, NHRA (Dadra & Nagar Tablets & Capsules – Bahrain, Medicine and Drug
Slide 7: Manufacturing Facilities: Formulations
Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections Silvassa WHO-GMP, TGA-Australia, Health-Canada, Tablets & Capsules (Dadra & Nagar Haveli) Local FDA Unit – I : WHO-GMP Dehradun, Tablets & Unit - II: WHO-GMP, GHANA-FDA, (Uttarakhand) Cephalosporin Injectables NAFDAC
Slide 8: Manufacturing Facilities: Active Pharmaceutical Ingredients (APIs)
Manufacturing Facilities Active Pharmaceutical Ingredients (APIs) 8
Slide 9: Manufacturing Facilities: APIs
Manufacturing Facilities APIs Location Approvals / Inspections TGA-Australia, EDQM, PMDA-Japan, WHO-Geneva, Health Canada, EU-GMP (LaGesso, Berlin), MOH Russia, Ratlam (Madhya Pradesh) MFDS (Korea), CDSCO- India, Cofepris (Mexico), EU WC, ANVISA (Brazil) Indore (Madhya Pradesh) WHO-Geneva, CDSCO- In
Slide 10: Revenue Break-up
Revenue Break-up 10
Slide 11: Revenue Break-up - Standalone
Revenue Break-up - Standalone 2021 - 22 25% Formulations Domestic Total 46% Total Revenue 54% API Exports 75% 11% 59% Formulations Formulations Exports Domestic 41% API API 89% 11
Slide 12: Revenue Break-up Standalone
Revenue Break-up Standalone 2021-22 2020-21 Rs. Crs Domestic Exports Total Domestic Exports Total Growth Branded Formulations 2508.27 415.99 2924.26 1981.67 403.42 2385.09 22.6% Generic/ Institution/ Tender Formulations - 1070.75 1070.75 - 1193.77 1193.77 -10.3% Total Formulations 2508.27 1486.74 39
Slide 13: Financials
S£ipca dose of life Financials
Slide 14: Financials - Standalone F.Y. 2021-22
Financials - Standalone F.Y. 2021 - 22 F.Y. 2020 - 21 % Rs. Crs US$ Mn Rs. Crs US$ Mn Growth Total Income 5455.49 733 5201.40 699 5% EBIDT 1268.20 170 1534.47 206 -17% EBIDT % 23.25% 29.50% PBT # 1088.36 146 1379.96 186 -21% PBT % 19.95% 26.53% PAT # 870.94 117 1140.77 153 -24% PAT % 15.96% 21.93% #
Slide 15: Financials - Standalone Profitability
Financials - Standalone Profitability FY 2021-22 FY 2020-21 PBIDT 23.25% 29.50% PBT 19.95% 26.53% PAT 15.96% 21.93% 15
Slide 16: Financials - Standalone Business Characteristics
Financials - Standalone Business Characteristics FY 2021-22 FY 2020-21 Return on Capital Employed % (PBIT / Capital Employed) 17.95% 27.97% Return on Net Worth % (PAT / Net Worth) 15.77% 24.00% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.30 2.54 Capital Employed Turnover Ratio (To
Slide 17: Financials - Standalone Growth
Financials - Standalone Growth FY 2021-22 FY 2020-21 Net Total Income 4.9% 17.4% Domestic Sales 19.7% 9.5% Export Sales -7.9% 26.7% PBIDT -17.4% 54.5% PBT -21.1% 75.8% Net Profit -23.7% 74.8% 17
Slide 18: Financials - Standalone Q1 FY23
Financials - Standalone Q1 FY23 Q1 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1488.09 192 1492.21 202 0% EBIDT 290.51 38 404.37 55 -28% EBIDT % 19.52% 27.10% PBT # 216.06 28 356.37 48 -39% PBT % 14.52% 23.88% PAT # 143.82 19 284.72 39 -49% PAT % 9.66% 19.08% # After forex gain of ` 3.22 Cr
Slide 19: Financials - Standalone Q2 FY23
Financials - Standalone Q2 FY23 Q2 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1521.47 191 1438.91 194 6% EBIDT 320.19 40 354.38 48 -10% EBIDT % 21.04% 24.63% PBT # 244.60 31 322.12 43 -24% PBT % 16.08% 22.39% PAT # 167.78 21 257.64 35 -35% PAT % 11.03% 17.91% # After forex loss of ` 11.66.
Slide 20: Financials - Standalone Q3 FY23
Financials - Standalone Q3 FY23 Q3 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1458.09 177 1341.71 179 9% EBIDT 255.28 31 315.12 42 -19% EBIDT % 17.51% 23.49% PBT # 171.83 21 272.24 36 -37% PBT % 11.78% 20.29% PAT # 120.27 15 218.17 29 -45% PAT % 8.25% 16.26% # After forex loss of ` 15.99.C
Slide 21: Financials - Standalone 9 Mths FY23
Financials - Standalone 9 Mths FY23 9 Mths FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 4467.65 561 4272.83 576 5% EBIDT 865.98 109 1073.87 145 -19% EBIDT % 19.38% 25.13% PBT # 632.49 79 950.73 128 -33% PBT % 14.16% 22.25% PAT # 431.87 54 760.53 102 -43% PAT % 9.67% 17.80% # After forex loss
Slide 22: Financials - Consolidated F.Y. 2021-22
Financials - Consolidated F.Y. 2021 - 22 F.Y. 2020 - 21 % Rs. Crs US$ Mn Rs. Crs US$ Mn Growth Total Income 5896.36 792 5482.83 737 8% EBIDT 1345.04 181 1565.89 210 -14% EBIDT % 22.81% 28.56% PBT # 1135.72 153 1388.98 187 -18% PBT % 19.26% 25.33% PAT # 884.08 119 1140.01 153 -22% PAT % 14.99% 20.79%
Slide 23: Financials - Consolidated Business Characteristics
Financials - Consolidated Business Characteristics FY 2021-22 FY 2020-21 Return on Capital Employed % (PBIT / Capital Employed) 18.61% 28.24% Return on Net Worth % (PAT / Net Worth) 15.88% 24.17% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.16 2.38 Capital Employed Turnover Ratio (
Slide 24: Financials - Consolidated Growth
Financials - Consolidated Growth FY 2021-22 FY 2020-21 Net Total Income 7.5% 16.3% Domestic Sales 22.7% 9.2% Export Sales -4.9% 24.1% PBIDT -14.1% 54.1% PBT -18.2% 86.0% Net Profit -22.4% 86.5% 24
Slide 25: Financials - Consolidated Q1 FY23
Financials - Consolidated Q1 FY23 Q1 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1607.85 208 1586.81 215 1% EBIDT 305.57 39 434.10 59 -30% EBIDT % 19.00% 27.36% PBT # 222.69 29 379.87 51 -41% PBT % 13.85% 23.94% PAT # 143.06 18 306.66 42 -53% PAT % 8.90% 19.33% # After forex gain of ` 3.46
Slide 26: Financials - Consolidated Q2 FY23
Financials - Consolidated Q2 FY23 Q2 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1637.18 205 1562.51 211 5% EBIDT 308.46 39 364.06 49 -15% EBIDT % 18.84% 23.30% PBT # 223.82 28 325.64 44 -31% PBT % 13.67% 20.84% PAT # 143.90 18 250.23 34 -42% PAT % 8.79% 16.01% # After forex loss of ` 11.59
Slide 27: Financials - Consolidated Q3 FY23
Financials - Consolidated Q3 FY23 Q3 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1576.89 192 1443.40 193 9% EBIDT 262.82 32 310.83 41 -15% EBIDT % 16.67% 21.53% PBT # 169.34 21 260.66 35 -35% PBT % 10.74% 18.06% PAT # 107.84 13 196.96 26 -45% PAT % 6.84% 13.65% # After forex loss of ` 16.07
Slide 28: Financials - Consolidated 9 Mths FY23
Financials - Consolidated 9 Mths FY23 9 Mths FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 4821.92 606 4592.72 619 5% EBIDT 876.85 110 1108.99 149 -21% EBIDT % 18.18% 24.15% PBT # 615.85 77 966.17 130 -36% PBT % 12.77% 21.04% PAT # 394.80 50 753.85 102 -48% PAT % 8.19% 16.41% # After forex lo
Slide 29: Contribution of Therapeutic Groups
Financials - Standalone Contribution of Therapeutic Groups Domestic Exports Therapeutic Segment 2021 – 22 2020 – 21 2021 – 22 2020 – 21 Non Steroidal Anti-Inflammatory Drugs (NSAID) 49% 52% 21% 28% Cardiovasculars & Anti-Diabetics 17% 19% 25% 23% Anti-Bacterials 7% 6% 6% 5% Anti-Malarials 5% 4% 24%
Slide 30: Branded Formulations: Domestic
Branded Formulations Domestic 30
Slide 31: Branded Formulations Domestic
Branded Formulations Domestic All India Rank IQVIA : 17th (MAT Dec’22). 24 Depots & 1 C&F agents. 17 Therapy Focused Marketing Divisions. Field Strength (PSR/ BA)– 5941 Over 4000 Wholesalers. 5 brands among top 300 brands (Zerodol-SP, Zerodol-P, HCQS, Zerodol TH & Folitrax). Market leaders in Rheuma
Slide 32: Branded Formulations Domestic Sales
Branded Formulations Domestic Rs. 2508.27 Crs US $ 337 Mn Rs. 1981.67 Crs Rs. 1912.61 Crs US$ 266 Mn Rs. 1646.83 Crs US$ 270 Mn US$ 232 Mn Sales 2018-19 2019-20 2020-21 2021-22 32
Slide 33: Branded Formulations Future Growth Drivers
Branded Formulations Domestic Future Growth Drivers Clinical research as a tool to launch innovative combination formulations / NDDS. Strong Brand building with focused promotion. In licensing/ out licensing to build business in the promoted therapy. Portfolio optimization, strategies to identify ne
Slide 34: International Business
S£ipca dose of life International Business
Slide 35: International Business
International Business Products of the company are now exported to over 100 countries across the globe. Recognized Star Trading House. 44% sales from exports. Field-force to promote brands in more than 35 countries of CIS, South East Asia, Middle East, Latin America and Africa. 35
Slide 36: International Business
International Business Marketing offices in Russia, Ukraine, Kazakhstan, Belarus , Vietnam, Philippines, Sri Lanka, Myanmar Kenya, Colombia, and Nigeria & Mexico (subsidiary company). Formulation dossiers for branded formulations registered in 57 countries. 36
Slide 37: International Business Sales
International Business Rs. 2717.19 Crs US$ 365 Mn Rs. 2502.69 Crs US $ 336 Mn Rs. 2143.75 Crs US$ 303 Mn Rs. 1730.84 Crs US$ 244 Mn Sales 2018-19 2019-20 2020-21 2021-22 37
Slide 38: Continent-wise Exports 2021-22
International Business Continent-wise Exports 2021 –22 (Rs. Crs) Bulk Drugs / % Continent Formulations Intermediates Total Contribution Europe 436.49 232.44 668.93 27% Africa 409.85 62.00 471.85 19% Americas 162.80 335.96 498.76 20% Asia 98.91 356.92 455.83 18% CIS 134.07 25.72 159.79 6% Australasia
Slide 39: International Formulations
International Formulations 39
Slide 40: International Formulations Sales
International Formulations Rs. 1597.19 Crs US$ 215 Mn Rs. 1486.74 Crs US $ 200 Mn Rs. 1221.55 Crs Rs. 1048.26 Crs US$ 172 Mn US$ 148 Mn Sales 2018-19 2019-20 2020-21 2021-22 40
Slide 41: International Branded Formulations
International Branded Formulations 41
Slide 42: International Branded Formulations Sales
International Branded Formulations Rs. 415.99 Crs US $ 56 Mn Rs. 403.42 Crs US$ 54 Mn Rs. 381.53 Crs US$ 54 Mn Rs. 360.94 Crs US$ 51 Mn Sales 2018-19 2019-20 2020-21 2021-22 42
Slide 43: International Branded Formulations Future Growth Drivers
International Branded Formulations Future Growth Drivers Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of new
Slide 44: International Generics
S£ipca dose of life International Generics
Slide 45: International Generics Sales
International Generics Sales Rs. 1193.77 Crs Products Products US$ 160 Mn Country Under Rs. 1070.75 Crs Registered Registration US $ 144 Mn Rs. 840.02 Crs US$ 119 Mn United Kingdom Rs. 687.32 Crs 85 13 / Europe US$ 97 Mn Australia / 73 2 New Zealand South Africa 52 11 2018-19 2019-20 2020-21 2021-22
Slide 46: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Future G
Slide 47: International APIs
S£ipca dose of life International APIs
Slide 48: International APIs Sales
International APIs Rs. 1120.00 Crs Rs. 1015.95 Crs US$ 151 Mn US $ 136 Mn Rs. 922.20 Crs US$ 130 Mn Rs. 682.58 Crs US$ 96 Mn Sales 2018-19 2019-20 2020-21 2021-22 48
Slide 49: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 1 Atenolol a a a CEP a 2 Artemether a a 3 Artesunate a 4 Artesunate Sterile a 5 Amodiaquine Hcl a 6 Amlodipine Besylate a a 7 Allopurinol a a CEP a 8 Atovaquone a 9 Benzarone a 10 Benz
Slide 50: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM Cetrizine Hydrochloride (CZ5/ CZ6 16 Process) a CEP 17 Chloroquine Phosphate a a 18 Chlorthalidone a 19 Chlorthalidone (CT3/CT7 Process) a 20 Chlorthalidone (CT7 Process) a 21 Chlortha
Slide 51: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 31 Frusemide a a a CEP a 32 Frusemide (Vetirinary) a 33 Glimepiride a a a 34 Hydrochlorothiazide (Process I) a a a CEP a 35 Hydrochlorothiazide (Process II) a a 36 Hydrochlorothiazide
Slide 52: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 46 Mesalamine (MZ4 Process) a 47 Mesalazine a 48 Mesalazine (MZ4B Process) a 49 Metformin HCL a a 50 Metformin HCL (ML Process) a 51 Metformin HCL (ML2 Process) a 52 Metoclopramide HCl
Slide 53: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 61 Ondansetron Hydrochloride a a CEP a 62 Ondansetron Base a a a 63 Olanzapine a 64 Paroxetine Hcl CEP a 65 Primaquine Phosphate a a 66 Piperaquine Phosphate a 67 Probenecid a 68 Progu
Slide 54: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM Risedronate Sodium Hemi- 76 Pentahydrate a 77 Ractopamine Hcl a a 78 Sodium Alendronate a a a 79 Telmisartan a 80 Telmisartan (WT3A Process) a 81 Torsemide a a 82 Tramadol Hydrochlorid
Slide 55: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 91 Venlafexine Hydrochloride a a 92 Warfarin Sodium Clathrate a a 93 Warfarin Sodium CEP a 94 Zaltoprofen a Total 53 23 7 14 18 55 Note : Australia accept CEP issued by EDQM 55
Slide 56: International APIs Future Growth Drivers
International APIs Future Growth Drivers Consolidate API business of Sartans across the globe. Long term strategic tie-ups with major South American/European formulators. Leverage the customer base of more than 1000 customers spread across 90 countries is well laid down platform to introduce Ipca ne
Slide 57: Research & Development: APIs & Formulations
Research & Development APIs & Formulations 57
Slide 58: R & D Spending
Research & Development APIs & Formulations R & D Spending Year Rs. Crs % to Sales 2017-18 118.10 3.73% 2018-19 89.35 2.50% 2019-20 101.04 2.35% 2020-21 126.67 2.49% 2021-22 141.46 2.65% 58
Slide 59: Research & Development APIs & Formulations
Research & Development APIs & Formulations Current scientist manpower of around 541 Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Bio-tech / fermentatio
Slide 60: Inception of Advanced Biotech Lab
Inception of Advanced Biotech Lab (Biosimilar R&D) Established “state of the art” R&D in 2015 Lashed with modern equipments and HTP devices Capable of In-house development from “Clone to Clinic” Scientific staff : 60+ Products: Mammalian based “mAbs” Microbial based “Non-mAbs” 60
Slide 61: Biosimilar Pipelines
Biosimilar Pipelines Molecules: Anti-cancer and Anti-inflammatory mAbs 6 monoclonal antibodies (mAbs) at various stage of the development Selected 5 Non-mAb Molecules for EU and USA Market 61
Slide 62: Thank you
Thank you No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited. This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in